Type 2 Diabetes Trial, Not Yet Recruiting NCT07515807 Sponsor: Weill Cornell Medical College in Qatar Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07515807
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older
  • People who are Qatari or of Arab background
  • People who have been admitted to hospital for a serious heart condition, either a sudden blockage or reduced blood flow to the heart (Acute Coronary Syndrome), or a sudden worsening of heart failure (Acute Heart Failure)
  • People who have diabetes (measured by a blood sugar level marker called HbA1c of 6.5% or higher, or any HbA1c level if the person is already taking medication to manage blood sugar) or pre-diabetes (HbA1c between 5.7% and 6.4%)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are not Qatari or not of Arab background
  • People who do not have diabetes or pre-diabetes, meaning their HbA1c blood sugar marker is below 5.7%
  • This trial is a review of existing medical records and does not involve any direct contact with individuals; people who are incarcerated are not a focus of this study, and incarceration status cannot be identified from the records being reviewed (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Charbel Abi Khalil, Weill Cornell Medicine-Qatar

Phone: + 974 4492 8484

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Weill Cornell Medical College in Qatar
Registry
ClinicalTrials.gov
Start date
16 July 2026
Est. completion
16 July 2030

Where this trial is recruiting

Qatar

Primary endpoints

Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients; Incidences of 2-point Major Adverse Cardiovascular Events (MACE) in Heart Failure Patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov